Reapplix, a Birkerod, Denmark-based developer of device technology for tissue regeneration, raised €2.7m in funding.
Backers included existing investors SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund).
The company intends to use the funds for pre-revenue value creation through to 2018, when it intends to raise further growth capital in order to undertake the full commercial launch of its lead product.
Led by Graeme Brookes, Chief Executive Officer, Reapplix is advancing LeucoPatch®, a device technology for tissue regeneration, which is currently being focused on wound care and is undergoing both clinical evaluation and commercial market testing.
In the system, blood is collected from the patient in a single use sevice, which is a precision engineered mini cell processor. The device, in combination with the LeucoPatch 3CP™ Centrifuge, uses patent protected technology to produce each autologous LeucoPatch on demand using a simple to use process, with no reagents, which fits in well with existing clinical work flow.